Meeting
2015 Genitourinary Cancers Symposium
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
Authors
Toni K. Choueiri
Dana-Farber Cancer Institute, Boston, MA
Toni K. Choueiri , M Dror Michaelson , Edwin M. Posadas , Guru Sonpavde , David F. McDermott , Meghara K. Walsh , Kevin C. Wall , Ben K. Seon , Manoj A. Jivani , Bonne J. Adams , Charles P. Theuer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01806064
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 426)
DOI
10.1200/jco.2015.33.7_suppl.426
Abstract #
426
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
First Author: Michael B. Atkins
Poster
2017 ASCO Annual Meeting
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
First Author: Yingmiao Liu
Poster
2016 Genitourinary Cancers Symposium
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
First Author: Tanya B. Dorff
Poster
2015 ASCO Annual Meeting
Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.
First Author: Tanya B. Dorff